Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | CCR9 | P51686 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13483912 | 0.84 | BDKRB1 (0.49) | BDKRB1KMT2ACCR9ALDH1A1SMN1; SMN2 | |
| SCHEMBL10251853 | 0.83 | BDKRB1 (0.74) | BDKRB1KMT2ACCR9TSHRALDH1A1 | |
| SCHEMBL14076579 | 0.83 | BDKRB1 (0.55) | BDKRB1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL8889074 | 0.82 | KMT2A (0.80) | KMT2ATSHRHSD17B10ALDH1A1KDM4E | |
| SCHEMBL7493986 | 0.79 | BDKRB1 (0.65) | BDKRB1KMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12197933 | 0.77 | BDKRB1 (0.83) | BDKRB1KMT2ACCR9ALDH1A1KDM4E | |
| SCHEMBL11708769 | 0.76 | KMT2A (1.00) | BDKRB1KMT2ATSHRHSD17B10ALDH1A1 | |
| SCHEMBL16474305 | 0.75 | KMT2A (0.68) | BDKRB1KMT2ATSHRHSD17B10ALDH1A1 | |
| SCHEMBL12143400 | 0.74 | KMT2A (0.55) | BDKRB1KMT2AALDH1A1KDM4E | |
| SCHEMBL16474313 | 0.74 | KMT2A (0.71) | BDKRB1KMT2ACCR9TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9035096-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140107160-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107160-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | BDKRB1 81/4885KMT2A 4473/4885CCR9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.